Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response

Annals of the Rheumatic Diseases

Volumn 67, Issue 7, 2008, Pages 917-925

  Thurlings, R M ^a   Vos, K ^b   Wijbrandts, C A ^a   Zwinderman, A H ^a   Gerlag, D M ^a   Tak, P P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD22 ANTIGEN; CD3 ANTIGEN; CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN M; PEPTIDE ANTIBODY; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SYNDECAN 1;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL IMAGING; DISEASE ACTIVITY; DRUG ACTIVITY; DRUG MECHANISM; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JOINT BIOPSY; LINEAR REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYNOVIUM; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 38149044612     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.080960     Document Type: Article

References (33)

1. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
2. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase HB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
3. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
4. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg DJ, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:772-8.
5. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008;67:402-8.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
8. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
9. Dolhain RJ, Ter Haar NT, De KR, Nieuwenhuis IG, Zwinderman AH, Breedveld FC, et al. Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol 1998;37:324-30.
10. Boyle DL, Rosengren S, Bugbee W, Kavanaugh A, Firestein GS. Quantitative biomarker analysis of synovial gene expression by real-time PCR. Arthritis Res Ther 2003;5:R352-60.
11. Smeets TJ, Barg EC, Kraan MC, Smith MD, Breedveld FC, Tak PP. Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann Rheum Dis 2003;62:635-8.
12. Liu YJ, Xu J, de BO, Parham CL, Grouard G, Djossou O, et al. Follicular dendritic cells specifically express the long CR2/CD21 isoform. J Exp Med 1997;185:165-70.
13. Kraan MC, Haringman JJ, Ahem MJ, Breedveld FC, Smith MD, Tak PP. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000;39:43-9.
14. Haringman JJ, Yinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP. Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther 2005;7:R862-7.
15. Kraan MC, Smith MD, Weedon H, Ahern MJ, Breedveld FC, Tak PP. Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis 2001;60:296-8.
16. Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G, et al. Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol 2005;35:1347-59.
17. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.
18. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
19. William J, Euler C, Shlomchik MJ. Short-lived plasmablasts dominate the early spontaneous rheumatoid factor response: differentiation pathways, hypermutating cell types, and affinity maturation outside the germinal center. J Immunol 2005;174:6879-87.
20. Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 1999;97:188-96.
21. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.
22. Kaser A, Dunzendorfer S, Offner FA, Ludwiczek O, Enrich B, Koch RO, et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol 2000;165:2474-80.
23. Krzysiek R, Lefevre EA, Zou W, Foussat A, Bernard J, Portier A, et al. Antigen receptor engagement selectively induces macrophage inflammatory protein-1 alpha (MIP-1 alpha) and MIP-1 beta chemokine production in human B cells. J Immunol 1999;162:4455-63.
24. Lund FE, Garvy BA, Randall TD, Harris DP. Regulatory roles for cytokine-producing B cells in infection and autoimmune disease. Curr Dir Autoimmun 2005;8:25-54.
25. Goodyear CS, Boyle DL, Silverman GJ. Secretion of BAFF by fibroblast-like synoviocytes from rheumatoid arthritis biopsies attenuates B cell depletion by rituximab. Arthritis Rheum 2005;52(Suppl 9):S290.
26. Terui Y, Sakurai T, Mishima Y, Mishima Y, Sugimura N, Sasaoka C, et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab. Cancer Sci 2006;97:72-9.
27. Ruderman EM, Weinblatt ME, Thurmond LM, Pinkus GS, Gravallese EM. Synovial tissue response to treatment with Campath-1H. Arthritis Rheum 1995;38:254-8.
28. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146- 54.
29. Abrahams VM, Cambridge G, Lydyard PM, Edwards JC. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fey receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000;43:608-16.
30. Braun A, Takemura S, Vallejo AN, Goronzy JJ, Weyand CM. Lymphotoxin beta-mediated stimulation of synoviocytes in rheumatoid arthritis. Arthritis Rheum 2004;50:2140-50.
31. Yanni G, Whelan A, Feighery C, Bresnihan B. Analysis of cell populations in rheumatoid arthritis synovial tissues. Semin Arthritis Rheum 1992;21:393-9.
32. Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
33. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.